LONDON, 9 Dec. 2013. Allerayde SAB Inc. (OTCQB:ASAB) has secured a grant from the European Space Agency to cover costs associated with the patent process and producing a working prototype of a new, integrated communicator device to be used in conjunction with AAA Pen.
As part of the grant process, Allerayde SAB has been invited to have its Research & Development Centre at Harwell, Oxford, U.K.
Allerayde SAB provides auto-injectors which provide adrenaline or epinephrine for people who experience anaphylactic shock, for instance in an allergic reaction. When the pen-shaped injectors are used, patients should seek medical attention to prevent further complications from the shock.
The pens will be outfitted with satellite navigation electronics that, when used, alert a local angel center of the user's location via a mobile phone network.
"Patients should get medical backup, and nine times out of ten, people just don't bother," says Michael Rhodes, CEO of Allerayde SAB Inc. "What's more, some collapse even after administering the drug. He estimates that of the few thousand pens that are used in cases of anaphylaxis annually in the US, some 800 die. I think it shows a great amount of belief in our vision for such applications of our products. If we are successful, which we believe we will be, if it saves just a hand full of lives a year the whole project would be deemed a success, but also the application could be ported to other devices."
